uniQure (QURE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
The 2026 Annual General Meeting will be held on June 10, 2026, in Amsterdam, with shareholders voting on key proposals affecting governance, compensation, capital structure, and corporate policy.
Shareholders can vote online, by phone, or by mail, and must notify the company in advance to attend in person.
The Board recommends voting in favor of all proposals and for annual advisory votes on executive compensation.
Voting matters and shareholder proposals
Proposals include adoption of 2025 Dutch statutory annual accounts, discharge of Board liability, reappointment of three non-executive directors, and designation of the Board to issue shares and limit pre-emptive rights.
Additional proposals cover Board authorization to repurchase shares, appointment of KPMG as external auditor, advisory approval of executive compensation, and frequency of say-on-pay votes.
Amendments to the 2014 Share Incentive Plan, Articles of Association for large company regime, increased authorized share capital, and a federal forum selection provision are also on the agenda.
Board of directors and corporate governance
The Board consists of one executive and seven non-executive directors, with staggered terms for stability and continuity.
Non-executive directors are nominated for three-year terms, with reappointments subject to shareholder approval.
Committees include Audit, Compensation, Nominating and Corporate Governance, Research & Development, and Commercial, all comprised of independent directors.
The Board structure supports long-term strategy and independence from management.
Latest events from uniQure
- AMT-130 BLA filing on track; $811.9M cash funds operations into 2030; pipeline shows promise.QURE
Q2 2026 - Q1 2026 brought higher revenue, a $53.5M net loss, and key regulatory and pipeline milestones.QURE
Q1 2026 - Shareholders will vote on governance, compensation, capital structure, and policy changes.QURE
Proxy filing - Key votes include director reappointments, auditor selection, and amendments to governance and share capital.QURE
Proxy filing - Huntington's therapy slowed progression in trials, but FDA seeks new phase III data.QURE
TD Cowen 46th Annual Health Care Conference - 2025 saw $16.1M revenue, strong cash, clinical progress, and ongoing regulatory hurdles.QURE
Q4 2025 - FDA alignment enables accelerated approval using Phase I/II data and cUHDRS as an endpoint.QURE
Study Update - AMT-130 slowed disease progression by 80% and reduced neurodegeneration biomarkers at 24 months.QURE
Study Update - FDA alignment enables AMT-130 BLA submission in Q1 2026, using Enroll-HD as external control.QURE
Status Update